Profile data is unavailable for this security.
About the company
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
- Revenue in USD (TTM)1.45m
- Net income in USD-142.88m
- Incorporated2011
- Employees19.00
- LocationAvalo Therapeutics Inc540 Gaither Rd Ste 400ROCKVILLE 20850-6713United StatesUSA
- Phone+1 (410) 522-8707
- Fax+1 (302) 636-5454
- Websitehttps://www.avalotx.com/
More ▼
Mergers & acquisitions
| Acquired company | AVTX:NAQ since announced | Transaction value |
|---|---|---|
| AlmataBio Inc | 184.63% | 20.92m |
Data delayed at least 15 minutes, as of Jul 08 2024 20:56 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardio Diagnostics Holdings Inc | 33.00k | -11.51m | 12.43m | 7.00 | -- | 3.90 | -- | 376.72 | -0.8257 | -0.8257 | 0.0021 | 0.1404 | 0.0051 | -- | -- | 4,714.29 | -178.70 | -- | -325.81 | -- | -- | -- | -34,872.12 | -- | -- | -4.84 | 0.0715 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| Bullfrog AI Holdings, Inc. | 65.00k | -5.95m | 12.48m | 4.00 | -- | 1.83 | -- | 192.04 | -0.8903 | -0.8903 | 0.0097 | 0.8667 | 0.0094 | -- | -- | 16,250.00 | -85.49 | -- | -103.85 | -- | 92.00 | -- | -9,129.42 | -- | -- | -278.20 | 0.0694 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -7.61m | 12.59m | 10.00 | -- | 1.68 | -- | -- | -0.5289 | -0.5289 | 0.00 | 0.4277 | 0.00 | -- | -- | 0.00 | -73.36 | -54.07 | -92.67 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| BioRestorative Therapies Inc | 149.50k | -6.96m | 12.66m | 11.00 | -- | 0.8737 | -- | 84.68 | -1.49 | -1.49 | 0.0302 | 2.14 | 0.0093 | -- | 5.86 | 13,590.91 | -43.44 | -192.11 | -49.49 | -329.32 | -- | -- | -4,653.34 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
| Imunon Inc | 0.00 | -18.85m | 12.79m | 33.00 | -- | 1.50 | -- | -- | -2.02 | -2.02 | 0.00 | 0.9041 | 0.00 | -- | -- | 0.00 | -66.82 | -50.18 | -91.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Avalo Therapeutics Inc | 1.45m | -142.88m | 13.02m | 19.00 | -- | -- | -- | 8.98 | -318.69 | -318.69 | 3.02 | -97.75 | 0.0181 | -- | 3.25 | 76,315.79 | -178.64 | -99.64 | -- | -154.42 | 54.90 | 84.69 | -9,853.73 | -613.58 | -- | -0.2415 | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Galecto Inc | 0.00 | -30.83m | 13.46m | 13.00 | -- | 0.4779 | -- | -- | -1.15 | -1.15 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -63.50 | -48.46 | -78.33 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 16.00m | 2.28m | 13.63m | 12.00 | -- | 0.3836 | 5.87 | 0.8522 | -14.38 | -14.38 | 10.88 | 11.96 | 0.5427 | -- | 8.64 | 1,333,333.00 | 9.52 | -70.52 | 10.17 | -81.86 | -- | -- | 17.55 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.17m | 13.79m | 3.00 | -- | 2.97 | -- | -- | -0.0184 | -0.0184 | 0.00 | 0.0269 | 0.00 | -- | -- | 0.00 | -34.05 | 27.48 | -34.48 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.25m | 13.82m | 16.00 | -- | 3.20 | -- | -- | -2.37 | -2.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -84.50 | -- | -107.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Aspira Women's Health Inc | 8.99m | -14.74m | 13.82m | 64.00 | -- | -- | -- | 1.54 | -1.33 | -1.33 | 0.8698 | -0.1104 | 0.9637 | 13.76 | 5.83 | 140,484.40 | -158.00 | -110.58 | -395.41 | -151.88 | 58.84 | 45.23 | -163.95 | -334.08 | 1.11 | -- | 3.10 | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -19.34m | 14.00m | 20.00 | -- | -- | -- | -- | -26.80 | -26.80 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -72.94 | -- | -92.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 12.39 | -- | -- | -- |
Data as of Jul 08 2024. Currency figures normalised to Avalo Therapeutics Inc's reporting currency: US Dollar USD
21.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Allostery Investments LPas of 17 Jun 2024 | 78.26k | 7.57% |
| Boothbay Fund Management LLCas of 17 Jun 2024 | 54.73k | 5.29% |
| Ikarian Capital LLCas of 31 Mar 2024 | 46.65k | 4.51% |
| Sio Capital Management LLCas of 31 Mar 2024 | 10.15k | 0.98% |
| Affinity Asset Advisors LLCas of 31 Mar 2024 | 10.00k | 0.97% |
| UBS Securities LLCas of 31 Mar 2024 | 7.71k | 0.75% |
| Adar1 Capital Management LLCas of 31 Mar 2024 | 6.00k | 0.58% |
| Natixis Investment Managers International SAas of 31 Mar 2024 | 2.51k | 0.24% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.12k | 0.21% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.64k | 0.16% |
More ▼
Data from 31 Mar 2024 - 17 Jun 2024Source: FactSet Research Systems Inc.
